The NS3 serine proteinase is regarded as one of the preferred targets for t
he development of therapeutic agents against hepatitis C virus (HCV), Possi
ble mechanisms of NS3 inhibitors include: ii) interference with the activat
ion of the enzyme by its NS4A cofactor: iii) binding to the structural zinc
site; and (iii) binding to the active site. These mechanisms have been exp
lored in detail by structural analysis of the enzyme.
(ii) The NS4A cofactor binds to the amino-terminal beta-barrel domain of th
e NS3 proteinase bringing about several conformational changes that result
in enzyme activation, The interaction betweeen NS3 and NS4A involves a very
large surface area and therefore it is not a likely target for the develop
ment of inhibitors. (ii) The NS3 proteinase contains a structural zinc bind
ing site. Spectroscopic studies have shown that changes in the conformation
of this metal-binding site correlate with changes in the specific activity
of the enzyme, and the NS3 proteinase is inhibited by compounds capable of
extracting zinc from its native coordination sphere. (iii) Based on the ob
servation that the NS3 proteinase undergoes inhibition by its cleavage prod
ucts, potent, active site-directed inhibitors have been generated. Kinetic
studies, site-directed mutagenesis, and molecular modelling have been used
to characterize the interactions between the NS3 proteinase and its product
inhibitors.